Trichuris Suis Ova (TSO)in Recurrent Remittent Multiple Sclerosis and Clinically Isolated Syndrome
Launched by CHARITE UNIVERSITY, BERLIN, GERMANY · Aug 9, 2011
Trial Information
Current as of April 29, 2025
Terminated
Keywords
ClinConnect Summary
TSO has an impact on the Th1-Th2 balance and effects Il-10 producing B-cells, mechanisms that result in an antiinflammatory effect.
A 12 month treatmet with TSO is safe and well-tolerated
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • active Recurrent remittent Multiple Scleosis or Clinically isolated Syndrome
- • inefficacy or intolerance for a therapy with Interferon-beta
- • age 18 - 65
- • EDSS \<4
- Exclusion Criteria:
- • secondary or primary chronic progressive Multiple Sclerosis
- • Immunomodulatoric or immunosuppressive therapy
About Charite University, Berlin, Germany
Charité - Universitätsmedizin Berlin is a leading academic medical center in Germany, renowned for its commitment to excellence in research, education, and patient care. As one of Europe's largest university hospitals, Charité integrates cutting-edge clinical practices with innovative research initiatives, fostering interdisciplinary collaboration across various medical fields. The institution is dedicated to advancing healthcare through rigorous clinical trials, contributing to the development of new therapies and treatment protocols. With a strong emphasis on translational medicine, Charité aims to bridge the gap between scientific discovery and practical application, ultimately enhancing patient outcomes and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Berlin, , Germany
Patients applied
Trial Officials
Berit Rosche, M.D.
Principal Investigator
Charité-University
Friedemann Paul, M.D.
Study Chair
Charité - University, NeuroCure Clinical Research Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials